The study co-authored by Associate Professor Kyle Rudser revealed increased stiffness in the abdominal aorta in children exposed to secondhand smoke.
The study co-led by Professor John Connett revealed no beneficial effect of beta blockers on the overall risk of exacerbations and strong evidence that using the drug was associated with severe exacerbations requiring hospitalization.
The project is led by Professor Haitao Chu and will create tools to aid medical researchers and decision-makers in understanding the benefits and risks of different diagnostic or treatment options.
This past June, PhD student Adam Kaplan traveled to Kampala, Uganda to teach data analysis software classes at the “UMN Hub” in Mulago hospital.
Assistant Professor Eric Lock is developing a method that will allow researchers to analyze different kinds of cancer and molecular cell data together.
Daynamica was co-developed by Associate Professor Julian Wolfson and captures detailed activity and travel information when people are driving, walking, biking, or using mass transit, such as riding a bus.
Biostatistics PhD student Roland Brown and recent graduate Chong Wu (PhD ‘18) won ENAR Distinguished Student Paper Awards, receiving a travel stipend to present their research at the ENAR Spring Meeting held March 24-27 in Philadelphia.
Assistant Professor Eric Lock has received a $1-million grant from the NIH to develop new methods to analyze multi-source and multi-way data all together at the same time.
Assistant Professor David Vock has been named a McKnight Presidential Fellow, a three-year award given to promising faculty members based on their research, scholarship, leadership, and ability to advance University of Minnesota priorities.
Research co-led by Professor Cavan Reilly shows Ebola survivors suffer from a range of health problems including body pain, eye conditions, and memory loss.
Faculty Joe Koopmeiners and David Vock will apply their methodology to data from 12 randomized trials of reduced-nicotine cigarettes to evaluate the impact of nicotine reduction as a regulatory policy.
SPH’s Coordinating Centers for Biometric Research leads global clinical trials to prevent and treat disease.